Skip to main content
. 2014 Apr 25;6(4):859–870. doi: 10.4161/mabs.28965

Table 3. Incidence of patients with persistent anti-therapeutic antibody response, following ADC administration in Phase 1.

Drug Incidence Effect on PK
Brentuximab vedotin 2/39 (5%) Reduced exposure
AVE9633 1/54 (2%) Not reported
huC242-DM1 0/37 (0%) None
Trastuzumab emtansine 1/22 (5%) None
MLN2704 0/23 (0%) None
PSMA ADC 0/53 (0%) None
SAR3419 1/39 (3%) None